IL213768A0 - 5-ht2a and 5-ht2b receptor antagonists for treating stenosis of the spinal canal - Google Patents

5-ht2a and 5-ht2b receptor antagonists for treating stenosis of the spinal canal

Info

Publication number
IL213768A0
IL213768A0 IL213768A IL21376811A IL213768A0 IL 213768 A0 IL213768 A0 IL 213768A0 IL 213768 A IL213768 A IL 213768A IL 21376811 A IL21376811 A IL 21376811A IL 213768 A0 IL213768 A0 IL 213768A0
Authority
IL
Israel
Prior art keywords
ht2a
receptor antagonists
spinal canal
ht2b receptor
treating stenosis
Prior art date
Application number
IL213768A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL213768A0 publication Critical patent/IL213768A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IL213768A 2008-12-23 2011-06-23 5-ht2a and 5-ht2b receptor antagonists for treating stenosis of the spinal canal IL213768A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172859 2008-12-23
PCT/EP2009/067768 WO2010072774A2 (de) 2008-12-23 2009-12-22 Mittel zur behandlung der spinalkanalstenose

Publications (1)

Publication Number Publication Date
IL213768A0 true IL213768A0 (en) 2011-07-31

Family

ID=40527906

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213768A IL213768A0 (en) 2008-12-23 2011-06-23 5-ht2a and 5-ht2b receptor antagonists for treating stenosis of the spinal canal

Country Status (11)

Country Link
EP (1) EP2367543A2 (de)
JP (1) JP2012513446A (de)
KR (1) KR20110098965A (de)
CN (1) CN102271667A (de)
AU (1) AU2009331469A1 (de)
BR (1) BRPI0923556A2 (de)
CA (1) CA2748163A1 (de)
IL (1) IL213768A0 (de)
MX (1) MX2011006852A (de)
SG (1) SG172315A1 (de)
WO (1) WO2010072774A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009405A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo ergolina y usos de estos.
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69919191T2 (de) 1998-09-01 2005-07-28 Nissan Chemical Industries, Ltd. Heilmittel für die stenose des rückenmarkkanals
WO2004043491A1 (ja) 2002-11-14 2004-05-27 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
US20070167403A1 (en) 2003-04-03 2007-07-19 Yoshifumi Takenobu Remedy for spinal canal stenosis
DE102006013307B3 (de) 2006-03-21 2007-10-04 Ergonex Pharma Gmbh Tergurid/Protergurid zur Behandlung von chronischen Schmerzen

Also Published As

Publication number Publication date
KR20110098965A (ko) 2011-09-02
MX2011006852A (es) 2011-07-20
AU2009331469A1 (en) 2011-07-21
BRPI0923556A2 (pt) 2016-01-26
EP2367543A2 (de) 2011-09-28
WO2010072774A3 (de) 2010-09-23
JP2012513446A (ja) 2012-06-14
WO2010072774A2 (de) 2010-07-01
SG172315A1 (en) 2011-07-28
CN102271667A (zh) 2011-12-07
CA2748163A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
GB0822590D0 (en) Orthotic prosthetic cushioned device and method of making the same
IL206284A0 (en) Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
PT2292231E (pt) Agente terapêutico para a estenose do canal espinal
IL196998A0 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
PL2405835T3 (pl) Urządzenie do odbudowy kostnej kręgosłupa
EP2413844A4 (de) Monolithisches orthopädisches implantat mit gelenkiger bearbeiteter oberfläche
ZA200905203B (en) Adjustable intervertebral implant
ZA201007771B (en) Prosthesis for cemented fixation and method for making the prosthesis
IL215690A0 (en) Thiazole derivatives and their use as p2y12 receptor antagonists
ZA201100697B (en) Orthopedic prosthesis
GB0703249D0 (en) Removal of spinal prostheses
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
ZA200900961B (en) Benzimidazole derivatives useful in treatment of vallinoid receptor TRPV1 related disorders
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
IL195900A0 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
IL198334A0 (en) 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as p2y12 receptor antagonists
EP2146573A4 (de) Einheitsdosisformulierungen und verfahren zur behandlung und prävention von thrombose mit einem thromboxanrezeptorhemmer
EP2475390A4 (de) Verfahren und zusammensetzungen zur behandlung rezeptortyrosinkinase-vermittelter erkrankungen oder leiden
IL193669A0 (en) Apparatus for the treatment of bruxism
GB0611154D0 (en) Novel receptor antagonists and their methods of use
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
ZA200901015B (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
GB0708613D0 (en) Toner, process for making toner and use of toner
ZA200900242B (en) Use of glucocorticoid receptor antagonists for treatment of infectious conditions
IL213768A0 (en) 5-ht2a and 5-ht2b receptor antagonists for treating stenosis of the spinal canal